<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TROSPIUM CHLORIDE</span><br/>(tro-spi'um)<br/><span class="topboxtradename">Sanctura<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">antispasmodic</span>; <span class="classification">anticholinergic (parasympatholytic) agent</span>; <span class="classification">antimuscarinic agent</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antagonizes the effect of acetylcholine on muscarinic receptors in smooth muscle. Its parasympatholytic action reduces the
         tonus of the smooth muscle of the bladder.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Trospium decreases urinary frequency, urgency, and urge incontinence in patients with overactive bladders.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of overactive (neurogenic) bladder with symptoms of urgency, frequency, and urge urinary incontinence.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to trospium; patients with or at risk for urinary retention; uncontrolled narrow-angle glaucoma; gastric
         tension, GI obstruction, ileus, pyloric stenosis, toxic megacolon, severe ulcerative colitis; pregnancy (category C). Safety
         and effectiveness in children have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Significant bladder obstruction, BPH; ulcerative colitis, GERD, intestinal atony; myasthenia gravis, autonomic neuropathy;
         moderate or severe hepatic dysfunction; severe renal insufficiency, renal failure; glaucoma; older adults; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Overactive Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg twice daily on empty stomach<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 20 mg twice daily on empty stomach, may decrease to 20 mg once daily at bedtime if anticholinergic adverse effects are intolerable<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at least 1 h before meals or on an empty stomach.</li>
<li>Store at 20°25° C (66°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fatigue. <span class="typehead">CNS<b></b> 			:</span> Headache. <span class="typehead">GI<b></b> 			:</span> <span class="speceff-common">Dry mouth, constipation</span> <i>,</i> abdominal pain, dyspepsia, flatulence. <span class="typehead">Special Senses:</span> Dry eyes. <span class="typehead">Urogenital<b></b> 			:</span> Urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug<b></b> 			:</span> Increased anticholinergic adverse effects with <span class="classification">anticholinergic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption<b></b> 			:</span> Peak<b></b> 			: 56 h. <span class="typehead">Elimination<b></b> 			:</span> Primarily excreted in feces (unabsorbed dose), renal tubular secretion of absorbed dose. <span class="typehead">Half-Life:</span> 20 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor bowel and bladder function. Report urinary hesitancy or significant constipation.</li>
<li>Withhold drug and notify physician if urinary retention develops.</li>
<li>Monitor for and report worsening of GI symptoms in those with GERD.</li>
<li>Frequent monitoring of IOP is required in those with controlled narrow-angle glaucoma.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: signs of an allergic reaction, (e.g., itching or hives), blurred vision or difficulty
            focusing, confusion, dizziness, difficulty passing urine.
         </li>
<li>Moderate intake of tea, coffee, caffeinated sodas, and alcohol to minimize side effects of this drug.</li>
<li>Avoid situations in which overheating is likely, as drug may impair sweating, which is a normal cooling mechanism.</li>
<li>Do not engage in hazardous activities until response to the drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>